# Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

> **NCT00538902** · PHASE2,PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 302 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Adalimumab 80 mg
- **BIOLOGICAL:** Adalimumab 40 mg

## Key facts

- **NCT ID:** NCT00538902
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-07
- **Final completion:** 2009-12
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2011-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00538902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00538902, "Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00538902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*